Page last updated: 2024-08-23

pravastatin and Neoplasms

pravastatin has been researched along with Neoplasms in 27 studies

Research

Studies (27)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (7.41)18.2507
2000's14 (51.85)29.6817
2010's9 (33.33)24.3611
2020's2 (7.41)2.80

Authors

AuthorsStudies
Gussekloo, J; Jukema, JW; le Cessie, S; Marijt, KA; Mooijaart, SP; Rostamian, S; Trompet, S; van Buchem, MA; van Hall, T1
Alexandre, L; Loke, YK; Thomas, JP1
Blankenberg, S; Elliott, J; Espinoza, D; Glasziou, PP; Hague, W; Keech, AC; Nestel, PJ; Robledo, KP; Simes, J; Stewart, RA; Sullivan, DR; Tonkin, AM; White, HD; Zeller, T1
Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG1
Garnett, DJ; Greenhough, TJ1
Ford, I; McCowan, C; Murray, H; Packard, CJ1
Xiao, H; Yang, CS1
Ravnskov, U1
Hattori, Y; Iwashita, M; Kaburagi, J; Matsushita, Y; Ozawa, M; Saito, H; Sugihara, M; Yoshida, S1
Bonovas, S; Nikolopoulos, G; Sitaras, NM2
Banciu, M; Cabaj, M; Coimbra, M; de Smet, L; Fens, MH; Metselaar, JM; Schiffelers, RM; Storm, G1
Chakraborty, K; Harirforoosh, S; Hsi, L; Krishnan, K; Menter, DG; Newman, RA; Ramsauer, VP; Yang, P1
Goldstein, MR1
Branchi, A; Fiorenza, AM; Sommariva, D1
Stefanec, T1
Hunt, D; Kirby, A; Liew, D; Magliano, D; Pater, H; Simes, J; Sundararajan, V; Tonkin, A1
Ajiki, W; Awata, N; Kobayashi, T; Sato, S1
Brophy, JM1
Bonovas, S; Sitaras, NM1
Archer, MC; Duncan, RE; El-Sohemy, A1
Alsheikh-Ali, AA; Han, H; Karas, RH; Maddukuri, PV1
Brophy, MT; Farwell, WR; Fiore, LD; Gaziano, JM; Lawler, EV; Lew, RA; Scranton, RE1
Cobbe, SM; Ford, I; Isles, CG; Lorimer, AR; MacFarlane, PW; McKillop, JH; Packard, CJ; Shepherd, J1
Aoyama, T; Iwata, H; Kami, M1

Reviews

7 review(s) available for pravastatin and Neoplasms

ArticleYear
Association of cognitive function with increased risk of cancer death and all-cause mortality: Longitudinal analysis, systematic review, and meta-analysis of prospective observational studies.
    PloS one, 2022, Volume: 17, Issue:1

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cognition; Cognitive Dysfunction; Female; Humans; Male; Neoplasms; Pravastatin; Prospective Studies

2022
Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials.
    European journal of clinical pharmacology, 2020, Volume: 76, Issue:12

    Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Pravastatin; Progression-Free Survival; Randomized Controlled Trials as Topic; Time Factors

2020
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
    American heart journal, 2019, Volume: 210

    Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment

2019
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
    International journal of cancer, 2008, Sep-01, Volume: 123, Issue:5

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac

2008
Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan.
    Pharmacoepidemiology and drug safety, 2010, Volume: 19, Issue:2

    Topics: Anticholesteremic Agents; Controlled Clinical Trials as Topic; Female; Humans; Japan; Male; Middle Aged; Neoplasms; Pravastatin; Risk Factors

2010
Does pravastatin promote cancer in elderly patients? A meta-analysis.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2007, Feb-27, Volume: 176, Issue:5

    Topics: Age Factors; Aged; Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Risk

2007
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials.
    Journal of the American College of Cardiology, 2007, Jul-31, Volume: 50, Issue:5

    Topics: Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Liver Diseases; Lovastatin; Neoplasms; Pravastatin; Rhabdomyolysis; Simvastatin

2007

Trials

4 trial(s) available for pravastatin and Neoplasms

ArticleYear
Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study.
    Journal of epidemiology, 2006, Volume: 16, Issue:5

    Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Neoplasms; Pravastatin; Proportional Hazards Models; Risk; Smoking

2006
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
    The New England journal of medicine, 1995, Nov-16, Volume: 333, Issue:20

    Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Humans; Hypercholesterolemia; Incidence; Male; Middle Aged; Myocardial Infarction; Neoplasms; Pravastatin; Risk; Survival Analysis

1995
Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group.
    Journal of clinical epidemiology, 1995, Volume: 48, Issue:12

    Topics: Adverse Drug Reaction Reporting Systems; Coronary Disease; Double-Blind Method; Enzyme Inhibitors; Follow-Up Studies; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medical Record Linkage; Medical Records Systems, Computerized; Middle Aged; Mortality; Myocardial Infarction; Neoplasms; Pravastatin; Prospective Studies; Risk Factors; Scotland

1995
Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study.
    Journal of atherosclerosis and thrombosis, 2000, Volume: 7, Issue:2

    Topics: Aged; Anticholesteremic Agents; Cerebral Infarction; Coronary Disease; Follow-Up Studies; Humans; Hypercholesterolemia; Japan; Lipids; Male; Middle Aged; Neoplasms; Patient Compliance; Pravastatin; Risk Factors

2000

Other Studies

16 other study(ies) available for pravastatin and Neoplasms

ArticleYear
D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease: LIPID Study.
    Circulation, 2018, 08-14, Volume: 138, Issue:7

    Topics: Adult; Aged; Biomarkers; Coronary Disease; Female; Fibrin Fibrinogen Degradation Products; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neoplasms; Pravastatin; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation; Venous Thromboembolism

2018
Statins cause profound effects on gene expression in human cancer cells in vitro: the role of membrane microdomains.
    Gene expression, 2012, Volume: 15, Issue:5-6

    Topics: Cell Line, Tumor; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Membrane Microdomains; Neoplasms; Pravastatin

2012
Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study.
    Circulation, 2016, Mar-15, Volume: 133, Issue:11

    Topics: Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus; Follow-Up Studies; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Mortality; Neoplasms; Pravastatin; Proportional Hazards Models; Randomized Controlled Trials as Topic; Scotland; Survival Analysis

2016
Re: The association between statins and cancer incidence in a veterans population.
    Journal of the National Cancer Institute, 2008, Jul-02, Volume: 100, Issue:13

    Topics: Anticholesteremic Agents; Antineoplastic Agents; Bias; Colorectal Neoplasms; Confounding Factors, Epidemiologic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lung Neoplasms; Male; Neoplasms; Pravastatin; Prostatic Neoplasms; Simvastatin; United States; Veterans

2008
Commentary on pravastatin and cancer: need for individual patient data meta-analyses.
    Pharmacoepidemiology and drug safety, 2010, Volume: 19, Issue:2

    Topics: Anticholesteremic Agents; Controlled Clinical Trials as Topic; Humans; Japan; Meta-Analysis as Topic; Middle Aged; Neoplasms; Pravastatin; Reference Standards

2010
Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation.
    Journal of controlled release : official journal of the Controlled Release Society, 2010, Dec-20, Volume: 148, Issue:3

    Topics: Angiogenic Proteins; Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokines; Genes, MHC Class I; Humans; Inflammation; Lipid Metabolism; Liposomes; Male; Mice; Mice, Inbred C57BL; Neoplasms; Pravastatin

2010
Efficacy and safety of more intensive lowering of LDL cholesterol.
    Lancet (London, England), 2011, Feb-26, Volume: 377, Issue:9767

    Topics: Age Factors; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Meta-Analysis as Topic; Neoplasms; Odds Ratio; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors

2011
Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Cell Division; Cell Line, Tumor; Chromatography, High Pressure Liquid; Fluorescent Antibody Technique; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microscopy, Fluorescence; Neoplasms; Pravastatin; Reverse Transcriptase Polymerase Chain Reaction; Simvastatin; Tandem Mass Spectrometry

2011
The PROSPER trial.
    Lancet (London, England), 2003, Feb-01, Volume: 361, Issue:9355

    Topics: Age Factors; Aged; Anticholesteremic Agents; Coronary Disease; Humans; Incidence; Killer Cells, Natural; Neoplasms; Patient Selection; Pravastatin

2003
The PROSPER trial.
    Lancet (London, England), 2003, Feb-01, Volume: 361, Issue:9355

    Topics: Aged; Anticholesteremic Agents; Humans; Hypercholesterolemia; Incidence; Neoplasms; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Research Design

2003
The PROSPER trial.
    Lancet (London, England), 2003, Feb-01, Volume: 361, Issue:9355

    Topics: Age Factors; Aged; Aging; Anticholesteremic Agents; Endothelial Growth Factors; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasms; Neovascularization, Pathologic; Pravastatin; Predictive Value of Tests; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2003
Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study.
    Australian and New Zealand journal of public health, 2003, Volume: 27, Issue:6

    Topics: Adult; Aged; Anticholesteremic Agents; Australia; Cardiovascular Diseases; Causality; Cohort Studies; Humans; Middle Aged; Mortality; Neoplasms; New Zealand; Pravastatin; Randomized Controlled Trials as Topic; Registries; Reproducibility of Results; Time

2003
Pravastatin and cancer: an unproven association.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2007, Feb-27, Volume: 176, Issue:5

    Topics: Age Factors; Aged; Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Neoplasms; Pravastatin; Risk Factors

2007
Statins and cancer.
    Epidemiology (Cambridge, Mass.), 2007, Volume: 18, Issue:4

    Topics: Case-Control Studies; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Odds Ratio; Pravastatin; Risk

2007
The association between statins and cancer incidence in a veterans population.
    Journal of the National Cancer Institute, 2008, Jan-16, Volume: 100, Issue:2

    Topics: Adult; Aged; Anticholesteremic Agents; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Neoplasms; Odds Ratio; Pravastatin; Proportional Hazards Models; Research Design; Retrospective Studies; Simvastatin; United States; Veterans

2008
Effects of pravastatin in the elderly.
    Annals of internal medicine, 2002, Jun-04, Volume: 136, Issue:11

    Topics: Aged; Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Neoplasms; Pravastatin; Risk Factors; Time Factors

2002